<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6110">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 14, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00569179</url>
  </required_header>
  <id_info>
    <org_study_id>0612-26/ IUCRO-0179</org_study_id>
    <nct_id>NCT00569179</nct_id>
  </id_info>
  <brief_title>A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies</brief_title>
  <official_title>A PHASE I TRIAL OF ALLOREACTIVE NK CELLS INFUSION FOLLOWING TRANSPLANTATION OF HAPLOTYPE MISMATCHED, KIR MISMATCHED HIGHLY PURIFIED CD34 CELLS IN PATIENTS WITH ADVANCED OR REFRACTORY MYELOID MALIGNANCIES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose of alloreactive NK
      cells that can be transfused following stem cell transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigate the maximum-tolerated dose (MTD) of highly-purified alloreactive NK cells infused following haplotype-mismatched, KIR ligand-mismatched transplants in patients with refractory hematological malignancies.</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess toxicity associated with the infusion of alloreactive NK cells</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the risk of acute and chronic GvHD following infusion of alloreactive NK cells.</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the feasibility of multiple harvesting and purifying NK cells to the relatively high-doses.</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the frequency and type of infections occurring within the first year following transplantation.</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe immune reconstitution following transplantation.</measure>
    <time_frame>through Day 128</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphoid</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Myelogenous, Chronic</condition>
  <arm_group>
    <arm_group_label>Alloreactive NK cell infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of alloreactive NK cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS CD34 Reagent System</intervention_name>
    <description>Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.</description>
    <arm_group_label>Alloreactive NK cell infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically documented AML, ALL, MDS, CML,

          -  Identification of haploidentical donor

          -  LVEF &gt; 45% corrected

          -  DLCO &gt; 50% predicted

          -  Serum Creatinine &lt;= 2 mg/dL

          -  Bilirubin &lt; 2 x ULN

          -  AST, ALT &lt; 2 x ULN

          -  Age â‰¤ 65 years

          -  Performance Status 0-1

        Exclusion Criteria:

          -  Patients relapsing &lt;6 months after autologous SCT are not eligible.

          -  Patients with active infections requiring oral or intravenous antibiotics are not
             eligible for enrollment until resolution of infection

          -  No HIV disease

          -  Non-pregnant and non-nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif Farag, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Wood, RN</last_name>
    <phone>317-944-1781</phone>
    <email>llwood@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherif Farag, MD, PhD</last_name>
    <phone>317-274-0843</phone>
    <email>ssfarag@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Wood, RN</last_name>
      <phone>317-944-1781</phone>
      <email>llwood@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sherif Farag, MD, PhD</last_name>
      <phone>317-274-0843</phone>
      <email>ssfarag@iupui.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloid Malignancies</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>MDS</keyword>
  <keyword>CML</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
